Firebrick Pharma Limited

ASX:FRE Stock Report

Market Cap: AU$11.1m

Firebrick Pharma Valuation

Is FRE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FRE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FRE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FRE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FRE?

Key metric: As FRE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for FRE. This is calculated by dividing FRE's market cap by their current revenue.
What is FRE's PS Ratio?
PS Ratio4x
SalesAU$2.75m
Market CapAU$11.14m

Price to Sales Ratio vs Peers

How does FRE's PS Ratio compare to its peers?

The above table shows the PS ratio for FRE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.5x
ACR Acrux
2.6x34.0%AU$13.1m
RNO Rhinomed
1.4xn/aAU$11.5m
ECS ECS Botanics Holdings
1.1xn/aAU$21.9m
IXC Invex Therapeutics
4.7xn/aAU$5.7m
FRE Firebrick Pharma
4xn/aAU$11.1m

Price-To-Sales vs Peers: FRE is expensive based on its Price-To-Sales Ratio (4x) compared to the peer average (2.5x).

Price to Sales Ratio vs Industry

How does FRE's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

16 CompaniesPrice / SalesEstimated GrowthMarket Cap
MYX Mayne Pharma Group
0.9x11.3%US$236.25m
PBP Probiotec
1.1x6.7%US$160.13m
VLS Vita Life Sciences
1.5xn/aUS$76.10m
VIT Vitura Health
0.5xn/aUS$37.04m
FRE 4.0xIndustry Avg. 4.9xNo. of Companies16PS01224364860+
16 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: FRE is good value based on its Price-To-Sales Ratio (4x) compared to the Australian Pharmaceuticals industry average (4.9x).

Price to Sales Ratio vs Fair Ratio

What is FRE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FRE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate FRE's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.14

7D

0%

1Y

10.2%

AVITA Medical

US$349.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.93

7D

2.3%

1Y

20.6%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

7D

-5.6%

1Y

-46.8%